Andrey Yu. Baranovsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrey Yu. Baranovsky has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir Trofimovich Ivashkin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
8 shared publications - Sergey A. Alekseenko
Far Eastern State Medical University
7 shared publications - O. P. Alekseyeva
Privolzhsky Research Medical University
6 shared publications - Oxana Yurievna Zolnikova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications - Vladislav Vladimirovich Tsukanov
Research Institute of Medical Problems of the North — Affiliated Branch of the Federal Research Center “Krasnoyarsk Science Center” of the Siberian Branch of the Russian Academy of Sciences
6 shared publications А. Ю. Барановский
ФГБОУ ВО «Санкт-Петербургский государственный университет
6 shared publications
Latest Publications
- 18 November 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 3
Principles of individualization of preventive and curative dietоtherapy on the example of diseases of the digestive system. Lecture
Dietetics currently belongs to those clinical disciplines for which there is high demand across all specialties without exception dealing with the prevention, treatment and rehabilitation of diseases in both adults and children. In many treatment systems, diet therapy is considered a leading and indispensable component of therapeutic and preventive measures. The lecture substantiates the principles of individualization of preventive nutrition for various population groups of examined individuals based on the results of disease prognosis. The algorithms for clinical and genetic disease forecasting developed by the authors are presented. The step-by-step implementation of comprehensive programs, taking into account disease risk factors, makes it possible to predict in advance the development of pathological processes and, on this basis, to design dietary preventive programs. The individualization of therapeutic diets using digestive diseases as an example is based on the basic use of standard diets established by the Order of the Ministry of Health of the Russian Federation No. 1008n dated September 23, 2020, "On approval of the procedure for providing patients with therapeutic nutrition." Appropriate modifications to the content of these diets, based on key findings from patient examinations, provide correction of metabolic disorders and nutritional deficiencies, block pathogenetic mechanisms of disease development, and regulate adaptive and compensatory processes. The lecture provides recommendations on the selection of necessary foods with proven therapeutic efficacy for various disorders of the digestive system, using specific clinical examples.
- 18 November 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 3
Principles of individualization of preventive and curative dietоtherapy on the example of diseases of the digestive system. Lecture
Dietetics currently belongs to those clinical disciplines for which there is high demand across all specialties without exception dealing with the prevention, treatment and rehabilitation of diseases in both adults and children. In many treatment systems, diet therapy is considered a leading and indispensable component of therapeutic and preventive measures. The lecture substantiates the principles of individualization of preventive nutrition for various population groups of examined individuals based on the results of disease prognosis. The algorithms for clinical and genetic disease forecasting developed by the authors are presented. The step-by-step implementation of comprehensive programs, taking into account disease risk factors, makes it possible to predict in advance the development of pathological processes and, on this basis, to design dietary preventive programs. The individualization of therapeutic diets using digestive diseases as an example is based on the basic use of standard diets established by the Order of the Ministry of Health of the Russian Federation No. 1008n dated September 23, 2020, "On approval of the procedure for providing patients with therapeutic nutrition." Appropriate modifications to the content of these diets, based on key findings from patient examinations, provide correction of metabolic disorders and nutritional deficiencies, block pathogenetic mechanisms of disease development, and regulate adaptive and compensatory processes. The lecture provides recommendations on the selection of necessary foods with proven therapeutic efficacy for various disorders of the digestive system, using specific clinical examples.
- Open Access
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 7-23
Gastroesophageal Reflux Disease and Barrett's Esophagus: Optimization of Patient Management and Cancer Prevention Measures (Literature Review and Resolution of the Expert Council of the Russian Gastroenterolog
Aim: to summarize current clinical guidelines and meta-analyses data, and to present the main statements of the Expert Council of the Russian Gastroenterological Association regarding the optimization of endoscopic diagnosis, morphological verification, pharmacotherapy, and management strategies for patients with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Key points. In the Russian Federation, GERD is a highly prevalent disease: according to a meta-analysis involving over 30,000 individuals, the frequency of heartburn and/or regurgitation occurring once a week or more is 25 %. Proton pump inhibitors (PPIs) represent the cornerstone drug class for the treatment of GERD. Rebamipide targets altered epithelial permeability and mucosal inflammation. Combination therapy with PPIs and rebamipide improves symptoms in patients with non-erosive reflux disease, leading to positive morphological changes in the esophageal mucosa and improved control of nocturnal esophageal acid exposure. Ursodeoxycholic acid (UDCA) may be added to GERD therapy in the presence of biliary reflux or reflux gastritis. The clinical significance of GERD is determined not only by its high prevalence, chronic relapsing course, and impaired quality of life, but also by its precancerous potential. In individuals with GERD, the prevalence of Barrett’s esophagus is approximately 7 %, while the incidence of adenocarcinoma and/or high-grade dysplasia in the presence of low-grade dysplasia is 1.73% annually. Risk factors for the development of Barrett’s esophagus include male sex, age over 50 years, frequent GERD symptoms, tobacco smoking, obesity, and a positive family history. The management of patients with Barrett’s esophagus requires strict adherence to endoscopic and histological diagnostic protocols. Long-term PPI pharmacotherapy remains the standard of chemoprevention against neoplastic progression, demonstrating superiority over surgical treatment. Timely screening of high-risk individuals and adherence to endoscopic surveillance intervals enable the detection of dysplasia and esophageal adenocarcinoma at early, treatable stages. Conclusion. The Expert Council members proposed algorithms for the treatment of acute GERD exacerbation and maintenance therapy, as well as for the diagnosis and surveillance of patients with Barrett’s esophagus, taking into account current evidence and principles of evidence-based medicine. The literature review and the proposed algorithms aim to provide informational support for general practitioners, internists, gastroenterologists, and endoscopists in order to improve the quality of healthcare delivery and ensure effective prevention of esophageal adenocarcinoma.
- 5 September 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (4) , 7-23
Open AccessGastroesophageal Reflux Disease and Barrett's Esophagus: Optimization of Patient Management and Cancer Prevention Measures (Literature Review and Resolution of the Expert Council of the Russian Gastroenterolog
Aim: to summarize current clinical guidelines and meta-analyses data, and to present the main statements of the Expert Council of the Russian Gastroenterological Association regarding the optimization of endoscopic diagnosis, morphological verification, pharmacotherapy, and management strategies for patients with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Key points. In the Russian Federation, GERD is a highly prevalent disease: according to a meta-analysis involving over 30,000 individuals, the frequency of heartburn and/or regurgitation occurring once a week or more is 25 %. Proton pump inhibitors (PPIs) represent the cornerstone drug class for the treatment of GERD. Rebamipide targets altered epithelial permeability and mucosal inflammation. Combination therapy with PPIs and rebamipide improves symptoms in patients with non-erosive reflux disease, leading to positive morphological changes in the esophageal mucosa and improved control of nocturnal esophageal acid exposure. Ursodeoxycholic acid (UDCA) may be added to GERD therapy in the presence of biliary reflux or reflux gastritis. The clinical significance of GERD is determined not only by its high prevalence, chronic relapsing course, and impaired quality of life, but also by its precancerous potential. In individuals with GERD, the prevalence of Barrett’s esophagus is approximately 7 %, while the incidence of adenocarcinoma and/or high-grade dysplasia in the presence of low-grade dysplasia is 1.73% annually. Risk factors for the development of Barrett’s esophagus include male sex, age over 50 years, frequent GERD symptoms, tobacco smoking, obesity, and a positive family history. The management of patients with Barrett’s esophagus requires strict adherence to endoscopic and histological diagnostic protocols. Long-term PPI pharmacotherapy remains the standard of chemoprevention against neoplastic progression, demonstrating superiority over surgical treatment. Timely screening of high-risk individuals and adherence to endoscopic surveillance intervals enable the detection of dysplasia and esophageal adenocarcinoma at early, treatable stages. Conclusion. The Expert Council members proposed algorithms for the treatment of acute GERD exacerbation and maintenance therapy, as well as for the diagnosis and surveillance of patients with Barrett’s esophagus, taking into account current evidence and principles of evidence-based medicine. The literature review and the proposed algorithms aim to provide informational support for general practitioners, internists, gastroenterologists, and endoscopists in order to improve the quality of healthcare delivery and ensure effective prevention of esophageal adenocarcinoma.
- Open Access
- 18 July 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 2,p. 5-16
The work of the registry of precancerous diseases is a real way of primary prevention of stomach cancer
Stomach cancer (RV) belongs to the category of oncological diseases of the digestive system, the prevention of which remains at a fairly high level, and measures to reduce it do not yet give the desired results. This article is a kind of report on the results of 5 years of work for the first time in the world of gastroenterology created a registry of patients with precancerous diseases of the stomach. A comparative analysis of the effectiveness of complex therapeutic and preventive work with patients included in the register (167 patients with atrophic gastritis with large intestinal metaplasia and 78 patients with atrophic gastritis with intestinal dysplasia), and 179 and 61 patients with similar morphological changes in the intestinal tract, respectively, were treated by therapists or gastroenterologists in local hospitals. polyclinics. Every year, after a control study and assessment of risk factors for prostate cancer, laboratory tests, FGDS and histological analysis of gastrobioptates, all patients underwent an automated prognosis of prostate cancer using the gastric cancer prognosis map developed by the author, which included an analysis of 36 risk factors for prostate cancer, followed by software of the data obtained in computer calculations of the degree of risk of prostate cancer. Patients in the study group with an alarming prognosis of breast cancer received individualized dynamic follow-up programs with recommendations for correcting breast cancer risk factors. Depending on the phase of the disease, they underwent prognostically based drug treatment with the inclusion of courses of the “gastro-oncoprotector” Regastim Gastro. The patients of the control group received different, but not systematic treatment complexes prescribed by the attending physicians of polyclinics. Oncoprotectors were not prescribed to them. The results of therapeutic and preventive work with patients included in the register of patients with precancerous diseases of the stomach showed, in comparison with patients in the control group, a higher motivation of patients in the fight against their established risk factors for prostate cancer, a decrease in the incidence of precancerous changes in the gastrointestinal tract - colonic metaplasia and dysplasia in 44.3% of patients, a decrease in the severity of atrophy CS in 38.5% of patients, a decrease in the number of patients with the development of prostate cancer by 14.0% compared with the control group. The high preventive efficacy of the oncoprotector Regastim Gastro has been proven in cases of unfavorable prognosis of prostate cancer in patients with atrophic gastritis.
- 18 July 2026
- Published by LLC Global Media Technology in Experimental and Clinical Gastroenterology
- No. 2,p. 5-16
Open AccessThe work of the registry of precancerous diseases is a real way of primary prevention of stomach cancer
Stomach cancer (RV) belongs to the category of oncological diseases of the digestive system, the prevention of which remains at a fairly high level, and measures to reduce it do not yet give the desired results. This article is a kind of report on the results of 5 years of work for the first time in the world of gastroenterology created a registry of patients with precancerous diseases of the stomach. A comparative analysis of the effectiveness of complex therapeutic and preventive work with patients included in the register (167 patients with atrophic gastritis with large intestinal metaplasia and 78 patients with atrophic gastritis with intestinal dysplasia), and 179 and 61 patients with similar morphological changes in the intestinal tract, respectively, were treated by therapists or gastroenterologists in local hospitals. polyclinics. Every year, after a control study and assessment of risk factors for prostate cancer, laboratory tests, FGDS and histological analysis of gastrobioptates, all patients underwent an automated prognosis of prostate cancer using the gastric cancer prognosis map developed by the author, which included an analysis of 36 risk factors for prostate cancer, followed by software of the data obtained in computer calculations of the degree of risk of prostate cancer. Patients in the study group with an alarming prognosis of breast cancer received individualized dynamic follow-up programs with recommendations for correcting breast cancer risk factors. Depending on the phase of the disease, they underwent prognostically based drug treatment with the inclusion of courses of the “gastro-oncoprotector” Regastim Gastro. The patients of the control group received different, but not systematic treatment complexes prescribed by the attending physicians of polyclinics. Oncoprotectors were not prescribed to them. The results of therapeutic and preventive work with patients included in the register of patients with precancerous diseases of the stomach showed, in comparison with patients in the control group, a higher motivation of patients in the fight against their established risk factors for prostate cancer, a decrease in the incidence of precancerous changes in the gastrointestinal tract - colonic metaplasia and dysplasia in 44.3% of patients, a decrease in the severity of atrophy CS in 38.5% of patients, a decrease in the number of patients with the development of prostate cancer by 14.0% compared with the control group. The high preventive efficacy of the oncoprotector Regastim Gastro has been proven in cases of unfavorable prognosis of prostate cancer in patients with atrophic gastritis.
- Open Access
- 8 July 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 1,p. 70-78
Small intestine bacterial overgrowth syndrome in elderly people of the North-Western Region of Russia
Introduction. The intestinal flora is considered by modern medicine as a separate system that performs a wide range of important functions in the human body, primarily regulatory and protective. Its role is particularly significant in older age groups. The aim of the study: to study the influence of the diet of elderly people on the development of small intestinal fibroids, the dependence of biological age and quality of life of older people on the severity of SIBR. Materials and methods. A total of 227 elderly people aged 67 to 85 years living in various regions of the North-Western region of Russia were examined. An assessment of the actual nutrition content (food diary) was carried out. A specific diagnosis of SIBR was performed using a hydrogen-methane breath test. The biological age was calculated using the method of L.M. Belozerova. The quality of life study was conducted using a non-specific SF-36 questionnaire. The results of the study . It was found that in the elderly, whose diet corresponded to modern principles of gerontodietology (WHO, 1988), SIBR was detected in 14 (26.9%) people, in the control group - 89.3%. The biological age in the study group exceeded the calendar age by 16.5± 3.2%, in the control group – by 22.3±4.1%. In elderly people with SIBR, compared with elderly people without SIBR, there was a significant negative difference in the characteristics of the elements of quality of life. The most significant negative differences were found in the analyses of role functioning (-15.7%), mental health (-23.3%), vital activity (-17.0%), and social functioning (-10.4%). Resume . It is concluded that a diet that does not correspond to the age-related physiology of an elderly person in the northwestern region of the Russian Federation significantly contributes to the occurrence of SIBR, which in turn significantly reduces the gerontoprotective capabilities of intestinal microbiocenosis, increasing the indicators of biological age, significantly reducing the quality of life of the elderly.
- 8 July 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 1,p. 70-78
Open AccessSmall intestine bacterial overgrowth syndrome in elderly people of the North-Western Region of Russia
Introduction. The intestinal flora is considered by modern medicine as a separate system that performs a wide range of important functions in the human body, primarily regulatory and protective. Its role is particularly significant in older age groups. The aim of the study: to study the influence of the diet of elderly people on the development of small intestinal fibroids, the dependence of biological age and quality of life of older people on the severity of SIBR. Materials and methods. A total of 227 elderly people aged 67 to 85 years living in various regions of the North-Western region of Russia were examined. An assessment of the actual nutrition content (food diary) was carried out. A specific diagnosis of SIBR was performed using a hydrogen-methane breath test. The biological age was calculated using the method of L.M. Belozerova. The quality of life study was conducted using a non-specific SF-36 questionnaire. The results of the study . It was found that in the elderly, whose diet corresponded to modern principles of gerontodietology (WHO, 1988), SIBR was detected in 14 (26.9%) people, in the control group - 89.3%. The biological age in the study group exceeded the calendar age by 16.5± 3.2%, in the control group – by 22.3±4.1%. In elderly people with SIBR, compared with elderly people without SIBR, there was a significant negative difference in the characteristics of the elements of quality of life. The most significant negative differences were found in the analyses of role functioning (-15.7%), mental health (-23.3%), vital activity (-17.0%), and social functioning (-10.4%). Resume . It is concluded that a diet that does not correspond to the age-related physiology of an elderly person in the northwestern region of the Russian Federation significantly contributes to the occurrence of SIBR, which in turn significantly reduces the gerontoprotective capabilities of intestinal microbiocenosis, increasing the indicators of biological age, significantly reducing the quality of life of the elderly.
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2)
The Combination of Anxiety and Depressive Disorders in Patients with Irritable Bowel Syndrome (Literature Review and Expert Council Resolution)
Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.
- 21 May 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (2)
The Combination of Anxiety and Depressive Disorders in Patients with Irritable Bowel Syndrome (Literature Review and Expert Council Resolution)
Aim : to review current understanding of the role of intestinal microbiota in the pathogenesis of irritable bowel syndrome (IBS), anxiety and depressive disorders, and to present the materials of the Expert Council, which met on April 19, 2025, in Moscow. Key points. A likely unifying factor in the development of IBS, anxiety, and depressive disorders is a change in the composition of the intestinal microbiota, which causes disruption of neuroendocrine, immune, and metabolic signaling pathways of interaction between the gut and brain (components of the gut-brain axis). The intestinal microbiota plays a coordinating role in maintaining the physiological constancy of these pathways. However, when its composition is disrupted, pathogenic mechanisms are activated, leading to the combined development of both IBS and anxiety and depressive disorders. Recent data have shown that patients with IBS, as well as those suffering from anxiety and depressive disorders, exhibit a unidirectional change in the composition of the intestinal microbiota, characterized by a decrease in the number of Bifidobacterium bacteria , suggesting their key role in the pathogenesis of these diseases. A pathogenetically substantiated therapeutic strategy for the combination of IBS and mental disorders includes modifying the gut microbiota using strain-specific pro biotics containing Bifidobacterium type species. Bifidobacterium longum 35624 and Bifidobacterium longum 1714 strains have demonstrated clinical efficacy in reducing the severity of IBS symptoms, anxiety, and depression. Conclusion . Prescribing a combination of Bifidobacterium longum 35624 and Bifidobacterium longum 1714 probiotic strains to patients with IBS, including those with comorbid mental disorders, is clinically justified. This combination of strains holds promise for inclusion in clinical guidelines for the management of patients with irritable bowel syndrome and mental and behavioral disorders.
- 1 April 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (1)
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Drug-Induced Liver Injury
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with drug-induced liver injury, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of drug-induced liver injury, peculiarities of its clinical course. Also, the recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for drug-induced liver injury disease and its clinical phenotypes assessment; approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician’s actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with drug- induced liver injury contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.
- 1 April 2026
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 36 (1)
Clinical Guidelines of the Russian Society for the Study of the Liver, Russian Gastroenterological Association, Russian Society for the Prevention of Non-Communicable Diseases, Russian Association of Endocrinologists, Russian Scientific Medical Society of Therapists, National Society of Preventive Cardiology, Russian Association of Gerontologists and Geriatricians on Drug-Induced Liver Injury
Aim. The clinical guidelines are intended to provide information support for making decisions by gastroenterologists, general practitioners and internists that will improve the quality of medical care for patients with drug-induced liver injury, taking into account the latest clinical data and principles of evidence-based medicine. Key points. Clinical guidelines contain information about current views on etiology, risk factors and pathogenesis of drug-induced liver injury, peculiarities of its clinical course. Also, the recommendations provide information on current methods of laboratory and instrumental diagnostics, invasive and non-invasive tools for drug-induced liver injury disease and its clinical phenotypes assessment; approaches to its treatment, considering the presence of comorbidities, features of dispensary monitoring and prophylaxis. The information is illustrated with algorithms of differential diagnosis and physician’s actions. In addition, there is information for the patient and criteria for assessing the quality of medical care. Conclusion. Awareness of specialists in the issues of diagnosis, treatment and follow-up of patients with drug- induced liver injury contributes to the timely diagnosis and initiation of treatment, which in the long term will significantly affect their prognosis and quality of life.
- Open Access
- 21 March 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (1) , 129-139
Therapeutic Nutrition for the Elderly with Mental Disorders
Background: therapeutic nutrition is an important component of the complex treatment of psychiatric patients, the individualization of which in the elderly requires special knowledge of gerontodietology. Scientifically based ideas about the nutrition specificities in mental disorders in elderly and senile people have not been sufficiently developed. The aim was to substantiate the need for differentiated approach to therapeutic nutrition in geriatric psychiatry. Discussion: generalization of gerontopsychiatric diseases pathogenetic concepts in the aspect of nutrition of old age people has scientific and practical significance. Degenerative (involutional) and vascular geneses, as well as combined (vascular-degenerative) pathogenesis, form organic brain lesions of varying severity and rate of progression. This is why the specificities of the course of mental disorders affect many metabolic processes in the body of the elderly. Studies have shown that 25–90% of elderly patients hospitalized in psychiatric hospitals experience the development of muscle wasting, about 50% suffer from protein-energy deficiency, hypovitaminosis, most often due to malnutrition. Therapeutic nutrition of psychiatric patients in both state and private medical institutions in Russia is provided in accordance with orders of the Ministry of Health using a unified nomenclature of diets (system of standard diets) to select a diet that compensates for metabolic deficiencies and involutional metabolic disorders, as well as eating disorders, associated with the influence of psychotropic pharmacotherapy, with its nutritional composition, Conclusion: the composition of diet types for different pathologies and in each specific clinical case depends on the characteristics of the course of the disease, its stage and pathogenesis, the state of the body's metabolic processes and eating disorders, associated with the influence of psychopharmacotherapy. The methodology for modifying differentiated diet needs considering last advances in understanding the problems of gerontology, geriatric psychiatry, comorbidity and pharmacological interactions.
- 21 March 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (1) , 129-139
Open AccessTherapeutic Nutrition for the Elderly with Mental Disorders
Background: therapeutic nutrition is an important component of the complex treatment of psychiatric patients, the individualization of which in the elderly requires special knowledge of gerontodietology. Scientifically based ideas about the nutrition specificities in mental disorders in elderly and senile people have not been sufficiently developed. The aim was to substantiate the need for differentiated approach to therapeutic nutrition in geriatric psychiatry. Discussion: generalization of gerontopsychiatric diseases pathogenetic concepts in the aspect of nutrition of old age people has scientific and practical significance. Degenerative (involutional) and vascular geneses, as well as combined (vascular-degenerative) pathogenesis, form organic brain lesions of varying severity and rate of progression. This is why the specificities of the course of mental disorders affect many metabolic processes in the body of the elderly. Studies have shown that 25–90% of elderly patients hospitalized in psychiatric hospitals experience the development of muscle wasting, about 50% suffer from protein-energy deficiency, hypovitaminosis, most often due to malnutrition. Therapeutic nutrition of psychiatric patients in both state and private medical institutions in Russia is provided in accordance with orders of the Ministry of Health using a unified nomenclature of diets (system of standard diets) to select a diet that compensates for metabolic deficiencies and involutional metabolic disorders, as well as eating disorders, associated with the influence of psychotropic pharmacotherapy, with its nutritional composition, Conclusion: the composition of diet types for different pathologies and in each specific clinical case depends on the characteristics of the course of the disease, its stage and pathogenesis, the state of the body's metabolic processes and eating disorders, associated with the influence of psychopharmacotherapy. The methodology for modifying differentiated diet needs considering last advances in understanding the problems of gerontology, geriatric psychiatry, comorbidity and pharmacological interactions.
- Open Access
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 106-112
Pathogenetic and metabolic basis of therapeutic nutrition in rheumatic diseases
Therapeutic and preventive nutrition is not only a means of providing patients with essential nutrients to meet the metabolic demands of the body, but also an important non-pharmacological method for correcting multiple pathogenetic mechanisms of disease, enhancing the effects of pharmacotherapy, and normalizing adaptive-compensatory and regulatory components of sanogenesis. Based on contemporary literature data and own data, the authors analyze the therapeutic effects of dietary components on key mechanisms involved in the development of rheumatic diseases (RDs). Algorithms for individualizing therapeutic nutrition programs for patients with major RDs are presented. Principles of modern clinical dietetics that may be of interest to practicing physicians are also discussed.
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 106-112
Open AccessPathogenetic and metabolic basis of therapeutic nutrition in rheumatic diseases
Therapeutic and preventive nutrition is not only a means of providing patients with essential nutrients to meet the metabolic demands of the body, but also an important non-pharmacological method for correcting multiple pathogenetic mechanisms of disease, enhancing the effects of pharmacotherapy, and normalizing adaptive-compensatory and regulatory components of sanogenesis. Based on contemporary literature data and own data, the authors analyze the therapeutic effects of dietary components on key mechanisms involved in the development of rheumatic diseases (RDs). Algorithms for individualizing therapeutic nutrition programs for patients with major RDs are presented. Principles of modern clinical dietetics that may be of interest to practicing physicians are also discussed.
- 30 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 14 (4) , 76-84
Comorbid conditions in gastric malignancies and their management in patients of the Northwestern federal district
Objective. To investigate risk factors and etiopathogenetically related comorbid conditions preceding the onset of gastric cancer (GC) to identify markers for early detection and potential prevention of malignant transformation. Materials and Methods. The retrospective study included 6.007 patients. All participants underwent esophagogastroduodenoscopy with gastric mucosal biopsy, testing for Helicobacter pylori, and selective autoimmune gastritis serological markers. Atrophic, inflammatory, and neoplastic changes of the gastric mucosa were evaluated. In patients with histologically confirmed GC, risk factors and comorbid conditions were analyzed. Results. GC of various histological types were identified in 126 patients. In 38 cases, biopsy sampling was performed according to the OLGA protocol. 33 were diagnosed with atrophic gastritis, including H. pylori-associated, autoimmune, and undifferentiated inactive gastritis. Non-atrophic H. pylori-associated gastritis was observed in 4 patients, while one patient had no inflammation in gastric mucosa. Hypochromic anemia was diagnosed in 15 patients, including 10 cases documented in the medical history; serum iron deficiency was detected in 12 patients and vitamin B12 deficiency in 6. Autoimmune thyroiditis and nodular goiter were identified in 12 patients, three of whom had previously undergone surgery for thyroid adenocarcinoma. Family history, smoking status, and alcohol consumption did not differ from population-based reference levels. Conclusion. Patients with GC exhibit a spectrum of clinically relevant comorbidities, including autoimmune thyroiditis, other autoimmune disorders, thyroid neoplasms, and anemia of various etiologies. These findings support the expansion of surveillance programs to include not only endoscopy but also targeted testing for H. pylori infection and markers of autoimmune gastritis.
- 30 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Evidence-Based Gastroenterology
- Vol. 14 (4) , 76-84
Comorbid conditions in gastric malignancies and their management in patients of the Northwestern federal district
Objective. To investigate risk factors and etiopathogenetically related comorbid conditions preceding the onset of gastric cancer (GC) to identify markers for early detection and potential prevention of malignant transformation. Materials and Methods. The retrospective study included 6.007 patients. All participants underwent esophagogastroduodenoscopy with gastric mucosal biopsy, testing for Helicobacter pylori, and selective autoimmune gastritis serological markers. Atrophic, inflammatory, and neoplastic changes of the gastric mucosa were evaluated. In patients with histologically confirmed GC, risk factors and comorbid conditions were analyzed. Results. GC of various histological types were identified in 126 patients. In 38 cases, biopsy sampling was performed according to the OLGA protocol. 33 were diagnosed with atrophic gastritis, including H. pylori-associated, autoimmune, and undifferentiated inactive gastritis. Non-atrophic H. pylori-associated gastritis was observed in 4 patients, while one patient had no inflammation in gastric mucosa. Hypochromic anemia was diagnosed in 15 patients, including 10 cases documented in the medical history; serum iron deficiency was detected in 12 patients and vitamin B12 deficiency in 6. Autoimmune thyroiditis and nodular goiter were identified in 12 patients, three of whom had previously undergone surgery for thyroid adenocarcinoma. Family history, smoking status, and alcohol consumption did not differ from population-based reference levels. Conclusion. Patients with GC exhibit a spectrum of clinically relevant comorbidities, including autoimmune thyroiditis, other autoimmune disorders, thyroid neoplasms, and anemia of various etiologies. These findings support the expansion of surveillance programs to include not only endoscopy but also targeted testing for H. pylori infection and markers of autoimmune gastritis.
- 29 December 2025
- Published by ECO-Vector LLC (Publications) in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 17 (4) , 70-76
The role of the Kimura–Takemoto standard classification in determining follow-up groups for the prevention of stomach cancer in residents of the Northwestern Federal District of Russia
BACKGROUND: Precancerous changes in the gastric mucosa identified during morphological examination often have macroscopic equivalents on endoscopy. In a number of studies comparing endoscopic and morphological changes in atrophic gastritis, the authors emphasized the limitations of applying these data depending on the region. It is relevant to conduct a similar study regarding the population of the Northwestern Federal District of Russia. AIM: To assess the prevalence of histological stages of gastric mucosal atrophy in different types and stages according to the Kimura–Takemoto endoscopic classification in the population of the Northwestern Federal District of Russia. METHODS: In a single-center cohort study, medical records of patients who underwent outpatient videoesophagogastroduodenoscopy between 2020 and 2022 were analyzed, and cases of gastric mucosal atrophy of any type according to the Kimura–Takemoto classification (173 men and 189 women) were selected. Gastric biopsies were obtained from five standard sites in accordance with the modified Sydney System, followed by morphological verification of the atrophy stage according to the Operative Link on Gastritis Assessment (OLGA) system, and the type and extent of intestinal metaplasia were determined when detected. RESULTS: From 1,188 medical records, 362 cases of gastric mucosal atrophy were selected. Kimura–Takemoto type C1 atrophy was detected in 123 patients; however, upon histological examination of biopsies, only 3 (2.4%) of them were found to have severe atrophy, which is an indication for dispensary endoscopic follow-up according to the recommendations of the Russian Gastroenterological Association and the Russian Endoscopic Society. Type C2 was detected in 98 patients, of whom 12 (12.2%) were found to have indications for follow-up based on the results of morphological analysis. Type C3 changes were detected in 47 patients, 14 (29.8%) of whom required follow-up. Signs of severe atrophy of types O1, O2, and O3 were detected in 28, 18, and 48 patients, respectively. Of these, 14 (50.0%), 13 (72.2%), and 31 (64.6%), respectively, required follow-up according to morphological analysis data. CONCLUSIONS: Open-type endoscopic atrophy (O1–O3) according to the Kimura–Takemoto classification demonstrated high concordance with histological signs of severe atrophy and intestinal metaplasia, and in the majority of cases, patients required further endoscopic follow-up. In contrast, in endoscopically mild C1-type atrophy, there were no signs of severe atrophy. In cases of limited resources and the absence of visual signs of atypia, biopsy may not be performed in this category of patients in routine practice.
- 29 December 2025
- Published by ECO-Vector LLC (Publications) in HERALD of North-Western State Medical University named after I.I. Mechnikov
- Vol. 17 (4) , 70-76
The role of the Kimura–Takemoto standard classification in determining follow-up groups for the prevention of stomach cancer in residents of the Northwestern Federal District of Russia
BACKGROUND: Precancerous changes in the gastric mucosa identified during morphological examination often have macroscopic equivalents on endoscopy. In a number of studies comparing endoscopic and morphological changes in atrophic gastritis, the authors emphasized the limitations of applying these data depending on the region. It is relevant to conduct a similar study regarding the population of the Northwestern Federal District of Russia. AIM: To assess the prevalence of histological stages of gastric mucosal atrophy in different types and stages according to the Kimura–Takemoto endoscopic classification in the population of the Northwestern Federal District of Russia. METHODS: In a single-center cohort study, medical records of patients who underwent outpatient videoesophagogastroduodenoscopy between 2020 and 2022 were analyzed, and cases of gastric mucosal atrophy of any type according to the Kimura–Takemoto classification (173 men and 189 women) were selected. Gastric biopsies were obtained from five standard sites in accordance with the modified Sydney System, followed by morphological verification of the atrophy stage according to the Operative Link on Gastritis Assessment (OLGA) system, and the type and extent of intestinal metaplasia were determined when detected. RESULTS: From 1,188 medical records, 362 cases of gastric mucosal atrophy were selected. Kimura–Takemoto type C1 atrophy was detected in 123 patients; however, upon histological examination of biopsies, only 3 (2.4%) of them were found to have severe atrophy, which is an indication for dispensary endoscopic follow-up according to the recommendations of the Russian Gastroenterological Association and the Russian Endoscopic Society. Type C2 was detected in 98 patients, of whom 12 (12.2%) were found to have indications for follow-up based on the results of morphological analysis. Type C3 changes were detected in 47 patients, 14 (29.8%) of whom required follow-up. Signs of severe atrophy of types O1, O2, and O3 were detected in 28, 18, and 48 patients, respectively. Of these, 14 (50.0%), 13 (72.2%), and 31 (64.6%), respectively, required follow-up according to morphological analysis data. CONCLUSIONS: Open-type endoscopic atrophy (O1–O3) according to the Kimura–Takemoto classification demonstrated high concordance with histological signs of severe atrophy and intestinal metaplasia, and in the majority of cases, patients required further endoscopic follow-up. In contrast, in endoscopically mild C1-type atrophy, there were no signs of severe atrophy. In cases of limited resources and the absence of visual signs of atypia, biopsy may not be performed in this category of patients in routine practice.